Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL-3) facility for performing research associated with Mtb is another limitation for the development of TB drug discovery. In our screening of BSL-1 Mycobacterium spp. against a battery of TB drugs, M. smegmatis (ATCC607) exhibits good agreement with its drug susceptibility against the TB drugs under a low-nutrient culture medium (0.5% Tween 80 in Middlebrook 7H9 broth). M. smegmatis (ATCC607) enters its dormant form in 14 days under a nutrient-deficient condition (a PBS buffer), and shows resistance to a majority of TB drugs, but shows susceptibility to amikacin, capreomycin, ethambutol, and rifampicin (with high concentrations) whose activities against non-replicating (or dormant) Mtb were previously validated.
Subscribe to Journal
Get full journal access for 1 year
only $27.17 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lauzardo M, Peloquin CA. Tuberculosis therapy for 2016 and beyond. Exp Opin Pharm. 2016;17:1859–72.
Siricilla S, Mitachi K, Wan B, Franzblau SG, Kurosu M. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors. J Antibiot. 2015;68:271–8.
Keri RS, Sasidhar BS, Nagaraja BM, Santos AM. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. Eur J Med Chem. 2015;100:257–69.
Muniyan R, Gurunathan J. Antimycobacterial activity of potential plant metabolites with emphasis on management of drug resistant Mycobacterium tuberculosis strains. Res J Biotech. 2017;12:75–86.
Liu J, Ren HP. Tuberculosis: current treatment and new drug development. Anti-Infect Agents Med Chem. 2006;5:331–44.
Tomioka H, Namba K. Development of antituberculous drugs: current status and future prospects. Tuberculosis. 2006;81:753–74.
Chatelain E, Ioset JR. Drug discovery and development for neglected diseases: the DNDi model. Drug Des Devel Ther. 2011;5:175–81.
Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2005;2:e302.
Mitachi K, Yun HG, Gillman CD, Skorupinska-Tudek K, Swiezewska E, Clemons WM, Kurosu M. Substrate tolerance of bacterial glycosyltransferase MurG: novel fluorescence-based assays. ACS Infect Dis. 2019; in press. https://doi.org/10.1021/acsinfecdis.9b00242.
Lemieux MR, Siricilla S, Mitachi K, Eslamimehr S, Wang Y, Yang D, Pressly JD, Kong Y, Park F, Franzblau SG, Kurosu M. An antimycobacterial pleuromutilin analogue effective against dormant bacilli. Bioorg Med Chem. 2018;26:4787–96.
Kurosu M. Vitamin K2 biosynthesis: drug targets for new antibacterials. Vitamin K2: vital for health and wellbeing. Gordeladze J. (ed.). IntechOpen, 2017. p. 281–95.
Mitachi K, Yun HG, Kurosu SM, Eslamimehr S, Lemieux MR, Klaic L, Clemons WM, Kurosu M. Novel FR-900493 analogues that inhibit the outgrowth of Clostridium difficile spores. ACS Omega. 2018;3:1726–39.
Mitachi K, Aleiwi BA, Schneider CM, Siricilla S, Kurosu M. Stereocontrolled total synthesis of muraymycin D1 having a dual mode of action against Mycobacterium tuberculosis. J Am Chem Soc. 2016;138:12975–80.
Mitachi K, Siricilla S, Yang D, Kong Y, Skorupinska-Tudek K, Swiezewska E, Franzblau SG, Kurosu M. Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors. Anal Biochem. 2016;512:78–90.
Siricilla S, Mitachi K, Skorupinska-Tudek K, Swiezewska E, Kurosu M. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I. Anal Biochem. 2014;461:36–45.
Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J Med Chem. 2012;55:3739–55.
Kurosu M, Crick DC. MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis. Med Chem. 2009;5:197–207.
Kurosu M, Narayanasamy P, Biswas K, Dhiman R, Crick DC. Discovery of 1,4-dihydroxy-2-naphthoate prenyltransferase inhibitors: New drug leads for multidrug-resistant Gram-positive pathogens. J Med Chem. 2007;50:3973–5.
Namouchi A, Cimino M, Favre-Rochex S, Charles P, Gicqul B. Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug. BMC Genomics. 2017;l18:530/1–9.
Agrawal P, Miryala S, Varshney U. Use of Mycobacterium smegmatis deficient in ADP-ribosyltransferase as surrogate for Mycobacterium tuberculosis in drug testing and mutation analysis. PLoS ONE. 2015;10:e0122076/1–13.
Chaturvedi V, Dwivedi N, Tripathi RP, Sinha S. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. J Gen Appl Microbiol. 2007;53:333–7.
Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother. 1997;41:2456–60.
Franzblau SG, Witzig RS, Mclaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol. 1998;36:362–6.
Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother. 1988;32:1131–6.
Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi region in India. Antimicrob Agents Chemother. 2010;54:4789–93.
Sorrentino F, Gonzalez del RR, Zheng X, Matilla JP, Gomez PT, Hoyos MM, Herran MEP, Losana AM, Av-Gay Y. Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages. Antimicrob Agents Chemother. 2016;60:640–5.
Wu X, Yang J, Tan G, Liu H, Liu Y, Guo Y, Gao R, Wan B, Yu F. Drug resistance characteristics of Mycobacterium tuberculosis isolates from patients with tuberculosis to 12 antituberculous drugs in China. Front Cell Infect Microbiol. 2019;9:345.
Phelan J, Maitra A, Gupta A, Bhakta S, McNerney R, Coll F, Nair M, Pain A, Clark TG. The draft genome of Mycobacterium aurum, a potential model organism for investigating drugs against Mycobacterium tuberculosis and Mycobacterium leprae. Int J Mycobacteriol. 2015;4:207–16.
Heinrichs MT, May RJ, Heider F, Reimers T, Sy SKB, Peloquin CA, Derendorf H. Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. Int J Mycobacteriol. 2018;7:156–61.
Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother. 1997;41:1004–9.
Rodrigues L, Villellas C, Bailo R, Viveiros M, Aínsa JA. Role of the mmr efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57:751–7.
Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, Alling T, Miller MJ, Parish T. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS ONE. 2013;8:e60531/1–9.
Mitchison DA, Zhang Y. Recent developments in the study of pyrazinamide: an update. Prog Resp Res. 2011;40:32–43.
Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 2003;52:790–5.
Mitachi K, Kurosu SM, Eslamimehr S, Lemieux MR, Ishizaki Y, Clemons WM, Kurosu M. Semi-synthesis of an anticancer DPAGT1 inhibitor from a muraymycin biosynthetic intermediate. Org Lett. 2019;21:876–9.
Kurosu M. Structure-based drug discovery by targeting N-glycan biosynthesis, dolichyl-phosphate N-acetylglucosaminephosphotransferase. Future Med Chem. 2019;11:927–33.
Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis. 2008;198:275–83.
Zhu JH, Wang BW, Pan M, Zeng YN, Rego H, Javid B. Rifampicin can induce antibiotic tolerance in mycobacteria via paradoxical changes in rpoB transcription. Nat Comm. 2018;9:1–13.
Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis—a molecular story. J Med Microbiol. 1998;47:189–96.
Moure R, Espanol M, Tudo G, Vicente E, Coll P, Gonzalez-Martin J, Mick V, Salvado M, Alcaide F. Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array. J Antimicrob Chemother. 2014;69:947–54.
Hazbon MH, Bobadilla del VM, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, Colangeli R, Safi H, Billman-Jacobe H, Lavender C, Fyfe J, Garcia-Garcia L, Davidow A, Brimacombe M, Leon CI, Porras T, Bose M, Chaves F, Eisenach KD, Sifuentes-Osornio J, Ponce de LA, Cave MD, Alland D. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother. 2005;49:3794–802.
Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, Musser JM, Jacobs WR. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med. 1997;3:567–70.
Sirgel FA, Tait M, Warren RM, Streicher EM, Boettger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Micro Drug Resist. 2012;18:193–7.
Fu LM, Shinnick TM. Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide GeneChips. J Infect. 2007;54:277–84.
Ho YM, Sun YJ, Wong SY, Lee ASG. Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2009;53:4010–2.
Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol. 2006;62:1220–7.
Vilchèze C, Jacobs WR. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007;61:35–50.
The National Center for Biotechnology Information. www.ncbi.nlm.nih.gov.
Imai T, Watanabe K, Mikami Y, Yazawa K, Ando A, Nagata Y, Morisaki N, Hashimoto Y, Furihata K, Dabbs ER. Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis. Micro Drug Resist. 1999;5:259–64.
Kurosu M. Cell wall biosynthesis and latency during tuberculosis infections In: Cirillo J, Kong Y, editors. Tuberculosis host-pathogen interactions. Cham: Springer; 2019. p. 1–21.
Mazurek J, Ignatowicz L, Kallenius G, Svenson SB, Pawlowski A, Hamasur B. Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells. PLoS ONE. 2012;7:e42515.
Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996;64:2062–9.
Anuchin AM, Mulyukin AL, Suzina NE, Duda VI, El-Registan GI, Kaprelyants AS. Dormant forms of Mycobacterium smegmatis with distinct morphology. Microbiology. 2009;155:1071–9.
Chen X, Hashizume H, Tomishige T, Nakamura I, Matsuba M, Fujiwara M, Kitamoto R, Hanaki E, Ohba Y, Matsumoto M. Delamanid kills dormant mycobacteria in vitro and in a guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2017;61:e02402/1–11.
Heifets L, Simon J, Pham V. Capreomycin is active against non-replicating M. tuberculosis. Ann Clin Microbiol Antimicrob. 2005;4:6.
Fattorini L, Piccaro G, Mustazzolu A, Giannoni F. Targeting dormant bacilli to fight tuberculosis. Mediterr J Hematol Infect Dis. 2013;5:e2013072.
Munsiff SS, Kambili CA, Shama D. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006;43:1468–75.
Raghunandanan S, Jose L, Kumar RA. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne’s model of dormancy. J Antibiot. 2018;71:939–49.
Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chem. 2008;61:323–31.
de Steenwinkel JEM, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, van Soolingen D, Bakker-Woudenberg IAJM. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65:2582–9.
Issar S. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003;16:463–96.
Chung GAC, Aktar ZJS, Duncan K. High-throughput screen for detecting antimycobacterial agents. Antimicrob Agents Chemother. 1995;39:2235–8.
Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 1988;32:1002–4.
Murray JF, Hopewell PC, Schraufnagel DE. Treatment of tuberculosis. A historical perspective. Ann Am Thorac Soc. 2015;12:1749–59.
Filippini P, Iona E, Piccaro G, Peyron P, Neyrolles O, Fattorini L. Activity of drug combinations against dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010;54:2712–5.
Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L. Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH. Antimicrob Agents Chemother. 2017;61:e02296-16/1–4.
The National Institutes of Health is greatly acknowledged for financial support of this work (Grant GM114611). MK thanks UTRF (University of Tennessee Health Science Center) for generous financial support (Innovation award R079700292). NMR data were obtained on instruments supported by the NIH Shared Instrumentation Grant. The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain H37Rv. JY thanks the support of Cystic Fibrosis Foundation Award (JI1810). This article is dedicated to the memory of Dr Isao Kitagawa, Professor Emeritus of pharmaceutical sciences at Osaka University, an inspirational scientist.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lelovic, N., Mitachi, K., Yang, J. et al. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. J Antibiot (2020). https://doi.org/10.1038/s41429-020-0320-7